tirzepatide as compared with semaglutide for the treatment of obesity vs semaglutide: A new battle in Tirzepatide on ingestive behavior in

Despite the limited number of patients, this study revealed no adverse effects with L-carnitine administration

Known cardiovascular disease as a precaution

Weeks 8-16: Further dose escalation

The SURPASS clinical trials have highlighted its significant A1C lowering and weight loss benefits, marking it as a promising option for patients with diabetes and obesity

Moving forward, it is essential to refine algorithm fusion strategies and enhance model transparency to better support early and reliable depression diagnosis

Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy